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Background: The role of the immune system in the pathophysiology of acute ischemic stroke is increasingly
recognized. However, targeted treatment strategies to modulate immunological pathways in stroke are still lacking.
Glatiramer acetate is a multifaceted immunomodulator approved for the treatment of relapsing-remitting multiple
sclerosis. Experimental studies suggest that glatiramer acetate might also work in other neuroinflammatory or
neurodegenerative diseases apart from multiple sclerosis.
Findings: We evaluated the efficacy of glatiramer acetate in a mouse model of brain ischemia/reperfusion injury.
60 min of transient middle cerebral artery occlusion was induced in male C57Bl/6 mice. Pretreatment with
glatiramer acetate (3.5 mg/kg bodyweight) 30 min before the induction of stroke did not reduce lesion volumes or
improve functional outcome on day 1.
Conclusions: Glatiramer acetate failed to protect from acute ischemic stroke in our hands. Further studies are
needed to assess the true therapeutic potential of glatiramer acetate and related immunomodulators in brain
ischemia.
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For many years ischemic stroke has been regarded as a
mere thrombo-embolic disease. However, there is increa-
sing evidence that the immune system is also critically
involved in stroke occurrence and development [1,2].
Brain ischemia triggers rapid activation of cerebral endo-
thelial cells and the release of danger signals from dying
neuronal tissues. As a consequence, different cell adhesion
receptors are upregulated and soluble chemoattractants
such as chemokines and cytokines are secreted that guide
the targeted invasion of innate immune cells (neutrophils,
macrophages) to the sites of tissue damage [2]. These per-
ipheral immune cells in concert with resident cell popula-
tions like microglia or astrocytes produce a potpourri of
potentially harmful mediators (e.g. reactive oxygen spe-
cies, degrading enzymes) and this sterile inflammation
further perpetuates the ischemic cascade. Interestingly,
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mice lacking functional T lymphocytes develop dramatic-
ally smaller brain infarctions and less severe functional
deficits after transient middle cerebral artery occlusion
[3-5]. Of note, distinct T cell subsets for instance regula-
tory T cells (Treg) or γδ T cells exist that are particularly
harmful in stroke [5]. Given that the immune system is of
significant relevance for the pathophysiology of acute is-
chemic stroke, it seems reasonable to evaluate the safety
and efficacy of specific immunomodulatory compounds in
terms of stroke prevention and treatment.
Glatiramer acetate (GA) is a synthetic peptide that con-
sists of four amino acids in a fixed molar residue ratio [6].
The substance for many years is in clinical use for the
treatment of relapsing-remitting multiple sclerosis and
has demonstrated to suppress experimental allergic en-
cephalomyelitis (EAE), the most common animal model
of multiple sclerosis [6]. The exact mode of action of GA
in autoimmune neuroinflammation is still unclear but
among other things is based on its ability to inhibit Th1
proinflammatory cytokines and to induce Th2 cell and
Treg activation or to reduce monocyte reactivity [7].
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a role [8]. However, the therapeutic potential of GA in
ischemic stroke is unclear and previous studies in rodents
produced controversial results [9,10]. Here, we investi-
gated the effect of GA on stroke outcome in a well-
established mouse model of brain ischemia/reperfusion
injury.
All experiments were approved by the respective insti-
tutional (University of Würzburg, Germany; University
of Münster, Germany) and governmental authorities
(Regierung von Unterfranken and Landesamt für Natur,
Umwelt und Verbraucherschutz Nordrhein-Westfalen).
Six to eight week old male C57Bl/6 mice weighing
20–25 g were used in the study which was conducted in
accordance with the recently published ARRIVE guide-
lines (http://www.nc3rs.org/ARRIVE). 60 min of transient
middle cerebral artery occlusion (tMCAO) using a mono-
filament was performed as described [11]. This model
mounts a strong and immediate local inflammatory re-
sponse in the ischemic brain [12]. GA (TEVA Pharma,
3.5 mg/kg bodyweight) [13] or vehicle (NaCl 0.9%) were
injected intravenously 30 min before tMCAO. Animals
were randomly assigned to the operators by an indepen-
dent person not involved in data acquisition and analysis.Figure 1 Glatiramer acetate (GA) does not protect from acute brain is
5-triphenyltetrazolium chloride stains of 3 corresponding coronal brain sectio
1 after transient middle cerebral artery occlusion (tMCAO). GA was applied 30
appeared to be similar between the two groups and this was confirmed by in
functional outcome on day 1 after tMCAO. The Bederosn score (left panel) an
and vehicle-treated controls (n = 5-7/group). Unpaired, 2-tailed Student’s t tes
n.s. = not significant.We performed surgery and evaluation of all read-out pa-
rameters while being blinded to the experimental groups.
Infarct volumes were calculated from coronal brain slices
stained with 2,3,5-triphenyltetrazolium chloride (TTC)
24 h after tMCAO [11]. The Bederson score [14] and the
grip test score [15] were assessed to monitor global neuro-
logic function, motor function, and coordination.
Stroke volumes were expressed as mean ± SEM. Func-
tional outcome parameters were depicted as scatter plots
including median with the 25% percentile and the 75%
percentile given in brackets in the text. For statistical ana-
lysis, the GraphPad Prism 5.0 software package (GraphPad
Software) was used. Data were tested for Gaussian dis-
tribution with the D’Agostino and Pearson omnibus
normality test and then analyzed by unpaired, two-tailed
Student´s t-test or Mann Whitney U test. P values < 0.05
were considered statistically significant.
Prophylactic administration of GA did not alter stroke
outcome (Figure 1). Stroke volumes on day 1 after 60 min
tMCAO were similar between GA-treated mice and vehicle-
treated controls (66.4 mm3± 37.3 mm3 vs. 76.7 mm3 ±
31.0 mm3, n = 7, p > 0.05) (Figure 1A). Accordingly,
no differences in functional outcome parameters were
observed (Bederson score: 3.0 [2.0, 3.0] vs 3.0 [1.0, 3.0],chemia/reperfusion injury. (A) (Left panel) Representative 2,3,
ns of a GA-treated mouse and a vehicle-treated mouse sacrificed on day
min before tMCAO at a dosage of 3.5 mg/kg bodyweight. Stroke sizes
farct volumetry (right panel) (n = 7/group). (B) GA did not improve
d the grip test (right panel) did not differ between GA-treated mice
t (infarct volumes) or Mann–Whitney Test (Bederson score, grip test);
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n = 5–7, p > 0.05) (Figure 1B).
The present study failed to demonstrate a protective
effect of GA in experimental stroke in mice even when
administered in a prophylactic setting. This is in line with
a previous investigation showing that GA does not reduce
stroke volumes or functional deficits on day 3 and day 7
after transient or permanent MCAO despite a downregu-
lation of pro-inflammatory cytokines [10]. In contrast,
Ibarra et al. [9] reported that GA exerts beneficial effects
on stroke outcome both histologically and clinically after
tMCAO in rats when applied 30 min after reperfusion.
However, in this study GA-induced neuroprotection be-
came manifest not before day 7. The exact reasons for
these discrepant findings are unclear at present but dif-
ferences in the stroke models (transient vs permanent) or
animal species (rat vs mice) used certainly play a role. In
addition, the dosing regimens including the time of
GA-application (prophylactic vs therapeutic) differed bet-
ween the two ancestor studies and ours.
GA has already been tested in other neurodegenerative
disease models apart from stroke and EAE but again
with divergent results [16]. While GA protected from
axonal and neuronal degeneration after optic nerve
crush [17,18] or in a mouse model of Alzheimer’s dis-
ease [19], the substance was ineffective in animal models
of amyotrophic lateral sclerosis [20,21]. However, even if
GA might mediate some neuroprotection in primarily
neurodegenerative diseases its application in ischemic
stroke appears less promising.
Several studies already exist that addressed the thera-
peutic potential of other immunomodulatory agents in
models of ischemic stroke. Treatment with FTY720,
which sequesters T lymphocytes within their lymphoid
organs [22] and which is also approved for the treatment
of multiple sclerosis, protects from ischemic neurodegen-
eration by reducing the interplay between thrombotic and
inflammatory processes (‘thrombo-inflammation’) in the
cerebral microvasculature [11]. However, other modes of
FTY720 action such as blood–brain barrier stabilization,
reduction of immune cell infiltration or direct neuropro-
tection might also play a role [23,24]. Similarly, blocking
of the very late antigen-4/vascular adhesion molecule-1
axis by injecting a monoclonal antibody against CD49d
(the murine equivalent of natalizumab) has been shown
to shield the brain against deleterious neuroinflamma-
tion after stroke in rodents [25,26] although an identical
approach was ineffective in our hands (unpublished
observations).
Our study has several limitations. First, we only focused
on the outcome at a very early stage after stroke (day 1).
Therefore, we cannot exclude neuroprotective effects of
GA that become operative only at more advanced stages
of infarct development [9]. Moreover, different GA dosingor application regimes could have produced different re-
sults. Finally, we refrained from conducting profound
mechanistic studies since we did not find an obvious
phenotype in GA-treated animals.
Taken together, our study failed to confirm a protective
effect of GA in acute ischemic stroke in mice. Neverthe-
less, the concept of immunomodulation in brain ischemia
is still tempting given the promising reports on other im-
munomodulatory agents. Further studies in relevant dis-
ease models are warranted.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PK and KG performed the experiments and drafted the manuscript. SGM and
CK conceived and funded the entire study and wrote the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We thank Melanie Glaser and Daniela Urlaub for excellent technical
assistance. This publication was funded by the German Research Foundation
(DFG) and the University of Würzburg in the funding programme Open
Access Publishing.
Author details
1Department of Neurology, University Hospital Würzburg, Josef-Schneider-Str.
11, 97080 Würzburg, Germany. 2Institute for Clinical Epidemiology and
Biometry and Comprehensive Heart Failure Centre, University of Würzburg,
Würzburg, Germany. 3Department of Neurology, University of Münster,
Albert-Schweitzer-Campus 1, Gebäude A1, Westturm, Ebene 05 48149
Münster, Germany. 4Institute of Physiology – Neuropathophysiology,
University of Münster, Münster, Germany.
Received: 17 February 2014 Accepted: 18 February 2014
Published: 27 February 2014
References
1. Magnus T, Wiendl H, Kleinschnitz C: Immune mechanisms of stroke.
Curr Opin Neurol 2012, 25:334–340.
2. Iadecola C, Anrather J: The immunology of stroke: from mechanisms to
translation. Nat Med 2011, 17:796–808.
3. Yilmaz G, Arumugam TV, Stokes KY, Granger DN: Role of T lymphocytes
and interferon-gamma in ischemic stroke. Circulation 2006,
113:2105–2112.
4. Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz T,
Austinat M, Nieswandt B, Wiendl H, Stoll G: Early detrimental T-cell effects
in experimental cerebral ischemia are neither related to adaptive
immunity nor thrombus formation. Blood 2010, 115:3835–3842.
5. Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Göbel K, Schuhmann MK,
Langhauser F, Helluy X, Schwarz T, Bittner S, Mayer CT, Brede M, Varallyay C,
Pham M, Bendszus M, Jakob P, Magnus T, Meuth SG, Iwakura Y, Zernecke A,
Sparwasser T, Nieswandt B, Stoll G, Wiendl H: Regulatory T cells are strong
promoters of acute ischemic stroke in mice by inducing dysfunction of
the cerebral microvasculature. Blood 2013, 121:679–691.
6. Dhib-Jalbut S: Mechanisms of action of interferons and glatiramer
acetate in multiple sclerosis. Neurology 2002, 58:S3–9.
7. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS,
Weber MS: Glatiramer acetate in the treatment of multiple sclerosis:
emerging concepts regarding its mechanism of action. CNS Drugs 2011,
25:401–414.
8. Kala M, Miravalle A, Vollmer T: Recent insights into the mechanism of
action of glatiramer acetate. J Neuroimmunol 2011, 235:9–17.
9. Ibarra A, Avendaño H, Cruz Y: Copolymer-1 (Cop-1) improves neurological
recovery after middle cerebral artery occlusion in rats. Neurosci Lett 2007,
425:110–113.
Kraft et al. Experimental & Translational Stroke Medicine 2014, 6:4 Page 4 of 4
http://www.etsmjournal.com/content/6/1/410. Poittevin M, Deroide N, Azibani F, Delcayre C, Giannesini C, Levy BI, Pocard M,
Kubis N: Glatiramer Acetate administration does not reduce damage after
cerebral ischemia in mice. J Neuroimmunol 2013, 254:55–62.
11. Kraft P, Göb E, Schuhmann MK, Göbel K, Deppermann C, Thielmann I,
Herrmann AM, Lorenz K, Brede M, Stoll G, Meuth SG, Nieswandt B,
Pfeilschifter W, Kleinschnitz C: FTY720 ameliorates acute ischemic
stroke in mice by reducing thrombo-inflammation but not by direct
neuroprotection. Stroke 2013, 44:3202–3210.
12. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA,
Arumugam TV, Orthey E, Gerloff C, Tolosa E, Magnus T: Temporal and
spatial dynamics of cerebral immune cell accumulation in stroke.
Stroke 2009, 40:1849–1857.
13. Scorisa JM, Freria CM, Victorio SC, Barbizan R, Zanon RG, Oliveira AL:
Glatiramer acetate treatment increases stability of spinal synapses and
down regulates MHC I during the course of EAE. Int J Biol Sci 2011,
7:1188–202.
14. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H:
Rat middle cerebral artery occlusion: evaluation of the model and
development of a neurologic examination. Stroke 1986, 17:472–476.
15. Moran PM, Higgins LS, Cordell B, Moser PC: Age-related learning deficits
in transgenic mice expressing the 751-amino acid isoform of human
beta-amyloid precursor protein. Proc Natl Acad Sci USA 1995,
92:5341–5345.
16. Schwartz M, Bukshpan S, Kunis G: Application of glatiramer acetate to
neurodegenerative diseases beyond multiple sclerosis: the need for
disease-specific approaches. BioDrugs 2008, 22:293–299.
17. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, Cohen IR, Schwartz M: T
cell immunity to copolymer 1 confers neuroprotection on the damaged
optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci
USA 2000, 97:7446–7451.
18. Smirnov I, Walsh JT, Kipnis J: Chronic mild stress eliminates the
neuroprotective effect of Copaxone after CNS injury. Brain Behav Immun
2013, 31:177–182.
19. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H,
Schwartz M: Glatiramer acetate fights against Alzheimer's disease by
inducing dendritic-like microglia expressing insulin-like growth factor 1.
Proc Natl Acad Sci USA 2006, 103:11784–11789.
20. Habisch HJ, Schwalenstöcker B, Danzeisen R, Neuhaus O, Hartung HP,
Ludolph A: Limited effects of glatiramer acetate in the high-copy number
hSOD1-G93A mouse model of ALS. Exp Neurol 2007, 206:288–295.
21. Haenggeli C, Julien JP, Mosley RL, Perez N, Dhar A, Gendelman HE,
Rothstein JD: Therapeutic immunization with a glatiramer acetate
derivative does not alter survival in G93A and G37R SOD1 mouse
models of familial ALS. Neurobiol Dis 2007, 26:146–152.
22. Chun J, Hartung HP: Mechanism of action of oral fingolimod (FTY720) in
multiple sclerosis. Clin Neuropharmacol 2010, 33:91–101.
23. Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH: Activation of
sphingosine 1-phosphate receptor-1 by FTY720 is Neuroprotective after
ischemic stroke in rats. Stroke 2010, 41:368–374.
24. Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, Guo S, Qin T,
Alsharif N, Brinkmann V, Liao JK, Lo EH, Waeber C: Fingolimod provides
long-term protection in rodent models of cerebral ischemia. Ann Neurol
2011, 69:119–129.
25. Liesz A, Zhou W, Mracskó É, Karcher S, Bauer H, Schwarting S, Sun L,
Bruder D, Stegemann S, Cerwenka A, Sommer C, Dalpke AH, Veltkamp R:
Inhibition of lymphocyte trafficking shields the brain against deleterious
neuroinflammation after stroke. Brain 2011, 134:704–720.
26. Relton JK, Sloan KE, Frew EM, Whalley ET, Adams SP, Lobb RR: Inhibition of
alpha4 integrin protects against transient focal cerebral ischemia in
normotensive and hypertensive rats. Stroke 2001, 32:199–205.
doi:10.1186/2040-7378-6-4
Cite this article as: Kraft et al.: Glatiramer acetate does not protect from
acute ischemic stroke in mice. Experimental & Translational Stroke Medicine
2014 6:4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
